Literature DB >> 12578858

Th2 bias of CD4+ NKT cells derived from multiple sclerosis in remission.

Manabu Araki1, Takayuki Kondo, Jenny E Gumperz, Michael B Brenner, Sachiko Miyake, Takashi Yamamura.   

Abstract

Although CD1d-restricted NKT cells have been implicated as a participant in the regulatory mechanism of autoimmune diseases, it remains unclear how they would regulate human autoimmune diseases such as multiple sclerosis (MS). Furthermore, although the NKT cells comprise CD4(+) and CD4(-) populations, prior studies have often represented them as simply a CD4(-) population. Given that CD4(+) and CD4(-) NKT cells may represent functionally distinct populations, it appears crucial to examine the individual NKT subset in autoimmune diseases. Here we studied the frequency and cytokine phenotypes of the CD4(+) and CD4(-) NKT cells in fresh peripheral blood mononuclear cells, and of alpha-galactosylceramide-stimulated short-term cell lines obtained during the remission or relapse phase of MS as compared with from healthy subjects (HS). Here we report that CD4(+) NKT line cells expanded from MS in remission (MS-rem) would produce a larger amount of IL-4 than those from HS or from MS in relapse (MS-rel). They were significantly biased for T(h)2 as judged by the IL-4/IFN-gamma balance. However, there was no functional bias toward T(h)1 or T(h)2 in CD4(-) NKT line cells from MS-rem due to the defects in both IFN-gamma and IL-4 production, compared with HS. Of note, although double-negative NKT cells in the periphery were greatly reduced, the reduction of CD4(+) NKT cells was only marginal, if any, in MS-rem compared with HS. The T(h)2 bias of CD4(+) NKT line cells from MS-rem may support an immunoregulatory role for the CD4(+) NKT cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12578858     DOI: 10.1093/intimm/dxg029

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  47 in total

1.  Immunoregulatory defects of V alpha 24V+ beta 11+ NKT cells in development of Wegener's granulomatosis and relapsing polychondritis.

Authors:  D Takagi; K Iwabuchi; C Iwabuchi; Y Nakamaru; S Maguchi; R Ohwatari; Y Furuta; S Fukuda; S Joyce; K Onoé
Journal:  Clin Exp Immunol       Date:  2004-06       Impact factor: 4.330

Review 2.  Going both ways: immune regulation via CD1d-dependent NKT cells.

Authors:  Dale I Godfrey; Mitchell Kronenberg
Journal:  J Clin Invest       Date:  2004-11       Impact factor: 14.808

Review 3.  Natural killer cells and their receptors in multiple sclerosis.

Authors:  Gurman Kaur; John Trowsdale; Lars Fugger
Journal:  Brain       Date:  2012-06-25       Impact factor: 13.501

Review 4.  The innate immune system in demyelinating disease.

Authors:  Lior Mayo; Francisco J Quintana; Howard L Weiner
Journal:  Immunol Rev       Date:  2012-07       Impact factor: 12.988

5.  Systemic analyses of immunophenotypes of peripheral T cells in non-segmental vitiligo: implication of defective natural killer T cells.

Authors:  Li Zhou; Kai Li; Yu-Ling Shi; Iltefat Hamzavi; Tian-Wen Gao; Marsha Henderson; Richard H Huggins; Oma Agbai; Bassel Mahmoud; Xiaofan Mi; Henry W Lim; Qing-Sheng Mi
Journal:  Pigment Cell Melanoma Res       Date:  2012-07-12       Impact factor: 4.693

Review 6.  Role of the innate immune system in the pathogenesis of multiple sclerosis.

Authors:  Roopali Gandhi; Alice Laroni; Howard L Weiner
Journal:  J Neuroimmunol       Date:  2010-04-15       Impact factor: 3.478

Review 7.  Natural killer T cells in multiple sclerosis and its animal model, experimental autoimmune encephalomyelitis.

Authors:  Luc Van Kaer; Lan Wu; Vrajesh V Parekh
Journal:  Immunology       Date:  2015-06-22       Impact factor: 7.397

8.  Invariant natural killer T cells in children with eosinophilic esophagitis.

Authors:  S Jyonouchi; C L Smith; F Saretta; V Abraham; K R Ruymann; P Modayur-Chandramouleeswaran; M-L Wang; J M Spergel; A Cianferoni
Journal:  Clin Exp Allergy       Date:  2014-01       Impact factor: 5.018

Review 9.  Potential role of NKT regulatory cell ligands for the treatment of immune mediated colitis.

Authors:  Madi El Haj; Ami Ben Ya'acov; Gadi Lalazar; Yaron Ilan
Journal:  World J Gastroenterol       Date:  2007-11-28       Impact factor: 5.742

Review 10.  The role of NKT cells in tumor immunity.

Authors:  Masaki Terabe; Jay A Berzofsky
Journal:  Adv Cancer Res       Date:  2008       Impact factor: 6.242

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.